Oramed soars on successful results with oral insulin capsule in T1DM

|About: Oramed Pharmaceuticals Inc. (ORMP)|By:, SA News Editor

Oramed Pharmaceuticals (ORMP) rises 34% in premarket trading.

The company says "patient responses positively correlated with administered doses, as did the duration of the effect," in a study testing the pharmacokinetic dose response of ORMD-0801 in type 1 diabetes.

ORMP will "continue to move forward with this indication" along with studies in type 2 diabetes. (PR)